Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Telix Pharmaceuticals ( (AU:TLX) ) is now available.
Telix Pharmaceuticals reported that Part 1 of its global Phase 3 ProstACT trial of TLX591-Tx, a first-in-class lutetium-177 PSMA-targeted radio antibody-drug conjugate for metastatic castration-resistant prostate cancer, met its primary safety and dosimetry objectives. The lead-in stage in 36 patients showed an acceptable safety and tolerability profile, largely low-grade non-hematologic events, manageable and transient hematologic toxicity, and radiation exposure well below organ safety limits, with no drug-drug interactions seen with standard therapies.
The positive data support continued expansion into Part 2 of the trial, which is already enrolling in multiple countries and will compare TLX591-Tx plus standard of care against standard therapy alone in roughly 490 patients. By reinforcing the feasibility of combining TLX591-Tx with widely used treatments such as abiraterone, enzalutamide and docetaxel, the results strengthen Telix’s position in PSMA-targeted radiopharmaceuticals and underscore the potential for TLX591-Tx to emerge as a new first-line option for men with advanced prostate cancer, pending further regulatory and clinical milestones.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$28.50 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals is a biopharmaceutical company focused on developing radiopharmaceuticals and radio antibody-drug conjugates for cancer diagnosis and treatment. The company’s pipeline targets prostate and other cancers using PSMA-directed and other molecularly targeted radiotherapies aimed at improving outcomes in advanced disease settings.
YTD Price Performance: -4.02%
Average Trading Volume: 2,834,796
Technical Sentiment Signal: Sell
Current Market Cap: A$3.64B
For detailed information about TLX stock, go to TipRanks’ Stock Analysis page.